Please login to the form below

Not currently logged in
Email:
Password:

Study into birth risks of epilepsy drugs

New research reveals that four of the most prescribed epilepsy drugs increase the risk of serious birth defects

Four of the most frequently prescribed epilepsy drugs appear to increase the risk of serious birth defects when taken early in pregnancy, according to a new study reported in The Lancet Neurology.

The research found that the higher the dosage of carbamazepine (Tegretol, Epitol), lamotrigine (Lamictal), valproic acid (Depakote) and phenobarbital, the greater the risk of defects in foetuses, according to the international team of researchers. However, they emphasised that the vast majority of women in their study delivered healthy children.

For their 11-year study, the researchers used data from the International Registry of Antiepileptic Drugs and Pregnancy on nearly 4,000 pregnancies in 33 countries. In all, 230 pregnancies resulted in major birth defects by the end of the first year after birth. Low doses of lamotrigine (less than 300mg per day) and carbamazepine (less than 400mg per day) carried the smallest risk, the study found.

The greatest risk to the foetus was seen with the highest doses of valproic acid (1,500 mg a day or more) and phenobarbital (150 mg or more a day), the researchers said.

A family history of major birth defects quadrupled the risk, they found.

The researchers said that their study shows that dose selection is as crucial as the choice of drug and gives doctors the opportunity to prescribe the safest anti-seizure medication at the safest level for women with epilepsy who want to get pregnant.

Most women with epilepsy need to take anti-seizure medication or risk harming themselves or their baby. Previous studies found that valproic acid, in particular, might increase the risk of birth defects, but those studies did not look at individual doses. Nor did they take into account other influential factors, such as family history of birth defects or severity of epilepsy.

Read the full study, 'Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry'.

7th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics